Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Cerilliant
Cipla
Johnson and Johnson
Accenture
QuintilesIMS
US Department of Justice
Express Scripts
Federal Trade Commission

Generated: July 17, 2018

DrugPatentWatch Database Preview

BRIVIACT Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Briviact, and what generic alternatives are available?

Briviact is a drug marketed by Ucb Inc and is included in three NDAs. There are three patents protecting this drug.

This drug has one hundred and forty-four patent family members in forty-one countries.

The generic ingredient in BRIVIACT is brivaracetam. One supplier is listed for this compound. Additional details are available on the brivaracetam profile page.
Summary for BRIVIACT
International Patents:144
US Patents:3
Applicants:1
NDAs:3
Suppliers / Packagers: 1
Bulk Api Vendors: 23
Clinical Trials: 3
Patent Applications: 265
DailyMed Link:BRIVIACT at DailyMed
Drug patent expirations by year for BRIVIACT
Generic Entry Opportunity Date for BRIVIACT
Generic Entry Dates for BRIVIACT*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
NDA:
Dosage::
SOLUTION;INTRAVENOUS
Generic Entry Dates for BRIVIACT*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
NDA:
Dosage::
SOLUTION;ORAL
Generic Entry Dates for BRIVIACT*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
NDA:
Dosage::
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for BRIVIACT
Mechanism of ActionEpoxide Hydrolase Inhibitors
Synonyms for BRIVIACT
(2S)-2-((4R)-2-oxo-4-n-propyl-1-pyrrolidinyl)butanamide
(2S)-2-((4R)-2-Oxo-4-propylpyrrolidin-1-yl)butanamide
(2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl]butanamide
(2s)-2-[(4r)-2-oxo-4-propylpyrrolidin-1-yl]butanamide
(S)-2-((R)-2-Oxo-4-propylpyrrolidin-1-yl)butanamide
1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphaS,4R)-
2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide
2(s)-[2-oxo-4(r)-propylpyrrolidin-1-yl]butyramide
357336-20-0
AK317303
AKOS027324306
AN-16688
BDBM50422531
Brivaracetam
Brivaracetam (USAN/INN)
Brivaracetam [USAN:INN]
Briviact (TN)
CHEBI:133013
CHEMBL607400
compound 83alpha
CS-3418
D08879
D0CT4D
DB05541
FT-0700965
GTPL9041
HY-14449
MFCD25976668
MSYKRHVOOPPJKU-BDAKNGLRSA-N
Rikelta
SCHEMBL122081
U863JGG2IA
UCB 34714
UCB-34714
UCB34714
UNII-U863JGG2IA
ZINC3979899

US Patents and Regulatory Information for BRIVIACT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-005 May 12, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-005 May 12, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Ucb Inc BRIVIACT brivaracetam SOLUTION;INTRAVENOUS 205837-001 May 12, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-002 May 12, 2016 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for BRIVIACT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,217,826 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Sign Up
7,358,276 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses ➤ Sign Up
6,713,635 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Sign Up
7,692,028 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for BRIVIACT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0815 Netherlands ➤ Sign Up PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: EU/1/15/1073 20160118
/2016 Austria ➤ Sign Up PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: EU/1/15/1073 (MITTEILUNG) 20160118
90009-4 Sweden ➤ Sign Up PRODUCT NAME: BRIVARACETAM; REG. NO/DATE: EU/1/15/1073 20150114
2016013,C1265862 Lithuania ➤ Sign Up PRODUCT NAME: BRIVARACETAMAS; REGISTRATION NO/DATE: EU/1/15/1073 20160114
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Fuji
QuintilesIMS
Boehringer Ingelheim
Merck
UBS
Mallinckrodt
Chinese Patent Office
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.